Key Drivers
- Strong Free Cash Flow
- Elevated Leverage
- High Intangibles
AIAI Summary
ELV is now an execution-and-cost-control investment: upside depends on sustaining its 90.2% benefit-expense ratio target and converting its $27+ adjusted EPS outlook into stronger GAAP earnings and $6B+ operating cash flow, while medical-cost inflation, government-program policy risk, leverage, and a richer valuation leave little room for misses.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Free Cash Flow
- •Elevated Leverage
- •High Intangibles
ELV offers solid cash generation and returns, but elevated leverage, intangible-asset reliance, and a richer valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Moderate monthly gain
- •Fading peak momentum
- •Critical support zone
ELV remains constructive over the last month but fading momentum below $418–$424 resistance warrants caution, with $400–$405 as key near-term support.
Declined 3.1% from the $424.24 peak to $410.95 within four days
Sentiment & News
Key News Insights:
- •Guidance Reaffirmed
- •Institutional Buying
- •Medicare Changes
Elevance Health's reaffirmed 2026 guidance and institutional buying support sentiment, though valuation debates and Medicare plan changes remain key watchpoints.
The news is modestly positive for Elevance shares, with execution on guidance and plan-transition management likely to determine further upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings